These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 33493919)

  • 21. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
    Basit A; Ali T; Rehman SU
    J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational discovery of dual potential inhibitors of SARS-CoV-2 spike/ACE2 and M
    Bekono BD; Onguéné PA; Simoben CV; Owono LCO; Ntie-Kang F
    Eur Biophys J; 2024 Aug; 53(5-6):277-298. PubMed ID: 38907013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection.
    Tai LT; Yeh CY; Chang YJ; Liu JF; Hsu KC; Cheng JC; Lu CH
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor.
    Kim YS; Chung HS; Noh SG; Lee B; Chung HY; Choi JG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting SARS-CoV-2 Spike Protein/ACE2 Protein-Protein Interactions: a Computational Study.
    Pirolli D; Righino B; De Rosa MC
    Mol Inform; 2021 Jun; 40(6):e2060080. PubMed ID: 33904240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
    Jokinen EM; Gopinath K; Kurkinen ST; Pentikainen OT
    IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1281-1289. PubMed ID: 33914685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
    Larue RC; Xing E; Kenney AD; Zhang Y; Tuazon JA; Li J; Yount JS; Li PK; Sharma A
    Bioconjug Chem; 2021 Jan; 32(1):215-223. PubMed ID: 33356169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pinpointing the potential hits for hindering interaction of SARS-CoV-2 S-protein with ACE2 from the pool of antiviral phytochemicals utilizing molecular docking and molecular dynamics (MD) simulations.
    Patel CN; Goswami D; Jaiswal DG; Parmar RM; Solanki HA; Pandya HA
    J Mol Graph Model; 2021 Jun; 105():107874. PubMed ID: 33647752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
    Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS
    J Biol Chem; 2021; 296():100759. PubMed ID: 33965375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation.
    Rui L; Haonan L; Wanyi C
    Biophys Chem; 2020 Dec; 267():106472. PubMed ID: 32916377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico exploration of small-molecule α-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2.
    Hakmi M; Bouricha ELM; Akachar J; Lmimouni B; El Harti J; Belyamani L; Ibrahimi A
    J Biomol Struct Dyn; 2022 Mar; 40(4):1546-1557. PubMed ID: 33023417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying compounds that prevent the binding of the SARS-CoV-2 S-protein to ACE2.
    Benítez-Cardoza CG; Vique-Sánchez JL
    Comput Biol Med; 2021 Sep; 136():104719. PubMed ID: 34358993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade.
    Han S; Zhao G; Wei Z; Chen Y; Zhao J; He Y; He YJ; Gao J; Chen S; Du C; Wang T; Sun W; Huang Y; Wang C; Wang J
    Peptides; 2021 Nov; 145():170638. PubMed ID: 34419496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants.
    Tanaka S; Nelson G; Olson CA; Buzko O; Higashide W; Shin A; Gonzalez M; Taft J; Patel R; Buta S; Richardson A; Bogunovic D; Spilman P; Niazi K; Rabizadeh S; Soon-Shiong P
    Sci Rep; 2021 Jun; 11(1):12740. PubMed ID: 34140558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
    Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
    Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.
    Othman H; Bouslama Z; Brandenburg JT; da Rocha J; Hamdi Y; Ghedira K; Srairi-Abid N; Hazelhurst S
    Biochem Biophys Res Commun; 2020 Jun; 527(3):702-708. PubMed ID: 32410735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
    Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
    Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2.
    Prajapat M; Shekhar N; Sarma P; Avti P; Singh S; Kaur H; Bhattacharyya A; Kumar S; Sharma S; Prakash A; Medhi B
    J Mol Graph Model; 2020 Dec; 101():107716. PubMed ID: 32866780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.